tirzepatide kidneys (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https tirzepatide and kidneys GLP therapies

In contrast, the class-level analysis assumes homogeneity across all GLP-1RAs, an assumption that does not always hold given population and pharmacologic differences across studies

The most commercially significant event in the GLP-1 market in 2026 is the opening of the generic semaglutide window

10.1111/ijs.12073 Int

This patient's nausea is driven by sustained GLP-1 receptor activation, not peak concentration

Blog Our Latest Blogs Preparing Your Mind for Weight Loss: Before and After Bariatric Surgery When most people think about bariatric surgery, they focus on the physical changes losing weight, feeling better, and living a healthier life